Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Micafungin versus placebo for pre-emptive treatment of invasive candidiasis in high-risk surgical ICU patients with intra-abdominal infection
NL-OMON34416Phase 2Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in invasive candidiasis and invasive mycoses comparing Mycamine with Placebo (2 arms). Primary endpoints: Incidence of invasive fungal infection and Time to invasive fungal infection. Started Jan 2011; status: active, not recruiting.
02
Drugs
micafungin
03
Conditions
invasive candidiasisinvasive mycoses
Beyond the preview
Go deeper on NL-OMON34416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34416.